Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways
International Journal of Experimental Pathology · 2024
DOI: 10.1111/iep.12519 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Experimental Pathology, 2024. Verfasst von Wesam F Farrash und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Oxidative Stress, Glucosides, Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Although single treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) or vitamin D 3 (VD 3 ) inhibited metabolic dysfunction‐associated steatohepatitis (MASH) development in diabetic patients, their combination has not been explored previously. Hence, this study investigated the hepatoprotective effects of SGLT2i (empagliflozin) and/or VD 3 against MASH in type 2 diabetic mice. Forty Mice were assigned into negative (NC) and positive (PC) controls, SGLT2i, VD 3 , and SGLT2i + VD 3 groups. All animals, except the NC group, received high‐fructose/high‐fat diet (8 weeks) followed by diabetes induction. Diabetic mice then received another cycle of high‐fructose/high‐fat diet (4 weeks) followed by 8 weeks of treatment (five times/week) with SGLT2i (5.1 mg/kg/day) and/or VD 3 (410 IU/Kg/day). The PC group demonstrated hyperglycaemia, dyslipidaemia, elevated liver enzymes, and increased non‐alcoholic fatty liver disease activity score (NAS) with fibrosis. Hepatic glucose transporting molecule (SGLT2) with lipogenesis (SREBP‐1/PPARγ), oxidative stress (MDA/H 2 O 2 ), inflammation (IL1β/IL6/TNF‐α), fibrosis (TGF‐β1/α‐SMA), and apoptosis (TUNEL/Caspase‐3) markers alongside the PI3K/AKT/mTOR pathway increased in the PC group. Conversely, hepatic insulin‐dependent glucose transporter (GLUT4), lipolytic (PPARα/INSIG1), antioxidant (GSH/GPx1/SOD1/CAT), and anti‐inflammatory (IL‐10) molecules with the inhibitor of PI3K/AKT/mTOR pathway (PTEN) decreased in the PC group. Whilst SGLT2i monotherapy outperformed VD 3 , their combination showed the best attenuation of hyperglycaemia, dyslipidaemia, and fibrosis with the strongest modulation of hepatic glucose‐transporting and lipid‐regulatory molecules, PI3K/AKT/mTOR pathway, and markers of oxidative stress, inflammation, fibrosis, and apoptosis. This study is the first to reveal boosted hepatoprotection for SGLT2i and VD 3 co‐therapy against diabetes‐induced MASH, possibly via enhanced metabolic control and modulation of hepatic PI3K/AKT/mTOR, anti‐inflammatory, anti‐oxidative, and anti‐fibrotic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
- Department of Anatomy, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia.
ORCID-Profile: Mohammad A Alobaidy, Bassem Refaat
Zitieren
APA
Farrash, W. F., Idris, S., Elzubier, M. E., Khidir, E. B. A., Aslam, A., Mujalli, A., Almaimani, R. A., Obaid, A. A., El-Readi, M. Z., Alobaidy, M. A., Salaka, A., Shakoori, A. M., Saleh, A. M., Minshawi, F., Samkari, J. A., Alshehre, S. M., & Refaat, B. (2024). Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways. International Journal of Experimental Pathology. https://doi.org/10.1111/iep.12519
Vancouver
Farrash WF, Idris S, Elzubier ME, Khidir EBA, Aslam A, Mujalli A, et al. Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways. International Journal of Experimental Pathology. 2024. doi:10.1111/iep.12519
BibTeX
@article{Farrash2024,
author = {Farrash, Wesam F and Idris, Shakir and Elzubier, Mohamed E and Khidir, Elshiekh B A and Aslam, Akhmed and Mujalli, Abdulrahman and Almaimani, Riyad A and Obaid, Ahmad A and El-Readi, Mahmoud Z and Alobaidy, Mohammad A and Salaka, Afnan and Shakoori, Afnan M and Saleh, Alaa M and Minshawi, Faisal and Samkari, Jamil A and Alshehre, Sallwa M and Refaat, Bassem},
title = {Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways},
journal = {International Journal of Experimental Pathology},
year = {2024},
doi = {10.1111/iep.12519}
}
EUVIMED